Organigram (TSE:OGI - Free Report) had its price target lowered by ATB Capital from C$5.25 to C$3.50 in a report published on Tuesday morning,BayStreet.CA reports.
Separately, Canaccord Genuity Group decreased their price target on shares of Organigram from C$3.60 to C$3.15 and set a "speculative buy" rating on the stock in a report on Monday, December 9th.
View Our Latest Stock Report on Organigram
Organigram Trading Up 4.6 %
Organigram stock traded up C$0.10 during trading on Tuesday, hitting C$2.28. The company's stock had a trading volume of 371,609 shares, compared to its average volume of 294,575. The stock's fifty day moving average is C$2.27 and its 200 day moving average is C$2.31. Organigram has a 1-year low of C$1.61 and a 1-year high of C$3.95. The stock has a market capitalization of C$247.54 million, a price-to-earnings ratio of -0.91, a P/E/G ratio of 0.42 and a beta of 1.13. The company has a debt-to-equity ratio of 1.13, a quick ratio of 2.62 and a current ratio of 6.95.
Insider Activity
In other Organigram news, Senior Officer Paolo De Luca sold 12,014 shares of the firm's stock in a transaction on Thursday, October 24th. The shares were sold at an average price of C$2.52, for a total transaction of C$30,275.28. Insiders own 31.32% of the company's stock.
About Organigram
(
Get Free Report)
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Featured Articles
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
